Bartlett & Co. LLC purchased a new position in Novo Nordisk A/S (NYSE:NVO) in the first quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 57,437 shares of the company’s stock, valued at approximately $3,458,000.

Several other large investors also recently modified their holdings of NVO. Davis R M Inc. raised its holdings in shares of Novo Nordisk A/S by 5.7% in the 1st quarter. Davis R M Inc. now owns 4,491 shares of the company’s stock worth $270,000 after purchasing an additional 241 shares in the last quarter. Baird Financial Group Inc. raised its holdings in shares of Novo Nordisk A/S by 1.4% in the 4th quarter. Baird Financial Group Inc. now owns 721,833 shares of the company’s stock worth $41,780,000 after purchasing an additional 9,937 shares in the last quarter. Huntington National Bank raised its holdings in shares of Novo Nordisk A/S by 31.8% during the fourth quarter. Huntington National Bank now owns 7,213 shares of the company’s stock valued at $417,000 after acquiring an additional 1,742 shares during the period. Conning Inc. acquired a new stake in shares of Novo Nordisk A/S during the fourth quarter valued at approximately $266,000. Finally, Connor Clark & Lunn Investment Management Ltd. raised its holdings in shares of Novo Nordisk A/S by 128.1% during the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 594,205 shares of the company’s stock valued at $34,393,000 after acquiring an additional 333,675 shares during the period. 7.20% of the stock is owned by institutional investors.

A number of research firms have recently issued reports on NVO. UBS Group lowered shares of Novo Nordisk A/S from a “buy” rating to a “neutral” rating in a report on Monday, May 11th. Bank of America upgraded shares of Novo Nordisk A/S from a “neutral” rating to a “buy” rating in a report on Monday, March 16th. ValuEngine upgraded shares of Novo Nordisk A/S from a “sell” rating to a “hold” rating in a report on Tuesday, March 3rd. Societe Generale reaffirmed a “sell” rating on shares of Novo Nordisk A/S in a research report on Thursday, May 7th. Finally, Cowen began coverage on shares of Novo Nordisk A/S in a research report on Monday, May 4th. They set a “market perform” rating and a $72.00 price objective on the stock. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and four have assigned a buy rating to the company. Novo Nordisk A/S presently has a consensus rating of “Hold” and a consensus target price of $163.55.

NVO stock traded down $0.38 during trading hours on Friday, hitting $63.91. The company’s stock had a trading volume of 846,405 shares, compared to its average volume of 2,000,828. The company has a market capitalization of $152.12 billion, a PE ratio of 25.06, a price-to-earnings-growth ratio of 2.26 and a beta of 0.46. Novo Nordisk A/S has a 12 month low of $46.47 and a 12 month high of $65.88. The stock has a 50 day moving average price of $61.38 and a two-hundred day moving average price of $59.18. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.05.

Novo Nordisk A/S (NYSE:NVO) last released its earnings results on Wednesday, May 6th. The company reported $0.75 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.68 by $0.07. The firm had revenue of $5 billion during the quarter, compared to analysts’ expectations of $4.70 billion. Novo Nordisk A/S had a net margin of 31.91% and a return on equity of 73.87%. Sell-side analysts expect that Novo Nordisk A/S will post 2.68 earnings per share for the current year.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, a healthcare company, engages in the development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral anti-diabetic products, obesity, and other chronic diseases.

Further Reading: The Discount Rate – What You Need to Know

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO).

Institutional Ownership by Quarter for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.